Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

13G Filing: Adage Capital Management and Sangamo Therapeutics Inc (SGMO)

Published on June 5, 2017 at 11:22 am by Insider Monkey Staff in Hedge Funds

Page 7 of 12

Page 7 of 12 – SEC Filing

Item 1(a).	NAME OF ISSUER
	The name of the issuer is Sangamo Therapeutics, Inc. (the “Company“).

Item 1(b).

ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

The Company’s principal executive offices are located at
501 Canal Boulevard, Richmond,

California 94804.

Item 2(a).	NAME OF PERSON FILING
	This statement is filed by:

Item 1(a).	NAME OF PERSON FILING
	This statement is filed by:

(i)

Adage Capital Partners, L.P., a Delaware limited partnership (“ACP“) with respect to the shares of Common Stock directly owned by it;

(ii)

Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP“), as general partner of ACP with respect to the shares of Common Stock directly owned by ACP;

(iii)

Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA“), as managing member of ACPGP, general partner of ACP, with respect to the shares of Common Stock directly owned by ACP;

(iv)

Robert Atchinson (“Mr. Atchinson“), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP; and

(v)

Phillip Gross (“Mr. Gross“), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP.

The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

	The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

Item 2(b).	ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
	The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd floor, Boston, Massachusetts 02116.

Follow Sangamo Therapeutics Inc (NASDAQ:SGMO)

Follow Sangamo Therapeutics Inc (NASDAQ:SGMO)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 7 of 12

NASDAQ:SGMO SEC 13G Filing Adage Capital Management Sangamo Therapeutics Inc. (SGMO)